News & Media

News Updates

Intelligent Bio Solutions Inc. Announces Reverse Stock Split

Intelligent Bio Solutions Inc. Announces Reverse Stock Split

NEW YORK, December 12, 2025 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will effect a 1-for-10 reverse split of its common stock, that will become effective at 11:59 pm (Eastern Time) on December 15, 2025.  Trading of the Company’s…

READ MORE >
Noble Conference

Intelligent Bio Solutions to Participate in Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference on December 2-3, 2025 

NEW YORK, November 20, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference, taking place over December 2-3, 2025, in Boca Raton, Florida.  Conference…

READ MORE >
INBS Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights

Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth

NEW YORK, November 12, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first quarter delivered record quarterly revenue of $1.11 million, driven…

READ MORE >
INBS Expects to Report Record Fiscal Q1 2026 Revenue

Intelligent Bio Solutions Expects to Report Record Fiscal First Quarter 2026 Revenue of Over $1 Million, an Increase of Approximately 32% Sequentially and 28% Year-Over-Year  

NEW YORK, November 04, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results for the fiscal first quarter ended September 30, 2025.   “We started fiscal year 2026 on a strong note, generating over $1 million in…

READ MORE >
INBS Secures 33 New Customer Accounts in Fiscal Q1 2026

Intelligent Bio Solutions Secures 33 New Customer Accounts in the Fiscal 2026 First Quarter, Showing Strong Year-Over-Year Growth and Increasing Total Active Accounts to 480

NEW YORK, October 30, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025, representing a 50% increase compared with the same…

READ MORE >
drug testing technology

Intelligent Bio Solutions Secures Major UK Contract with Multinational Industrial Service Provider

NEW YORK, October 23, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major new contract with one of the United Kingdom’s largest industrial service providers.  The multinational company, a global leader operating across the energy,…

READ MORE >
Intelligent Bio Solutions at their expo booth at Sydney Safety Event

Fingerprint Drug Testing at the Workplace Health & Safety Show Sydney 2025

The Workplace Health & Safety Show (WHS Show) returns to Sydney this October as the flagship event in Australia’s leading series dedicated to workplace health and safety. Held during National Safe Work Month, the WHS Show Sydney draws together over 6,000 professionals and 200+ exhibitors for two days of knowledge-sharing, networking, and innovation. Drug use in the…

READ MORE >
Webinar- Introducing Fingerprint Drug Testing

Webinar: Beyond Urine and Saliva – Introducing Fingerprint Drug Testing

Time: 4PM AEDT | 9AM GST | 2PM JST | 10:30AM IST Discover a faster, non-invasive, and more efficient approach to workplace drug testing. See firsthand how fingerprint drug testing streamlines sample collection, reduces labor, and improves compliance. Explore the limitations and challenges of traditional workplace drug testing methods, including urine and saliva. See how…

READ MORE >
INBS Provides Updated Timeline for Anticipated FDA Submission

Intelligent Bio Solutions Advances Preparations and Provides Updated Timeline for Anticipated FDA 510(k) Submission and Clearance

NEW YORK, September 26, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today is providing an update on the timeline for anticipated FDA 510(k) clearance for the use of its Intelligent Fingerprinting Drug Screening System for the opiate codeine.    Following recent…

READ MORE >
INBS Reports Fiscal 2025 Fourth Quarter and Full Year Results

Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies

NEW YORK, August 15, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. Fiscal 2025 marked a year of growth for the Company, driven by…

READ MORE >
INBS Announces Preliminary Q4 Double Digit Revenue

Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational Momentum

NEW YORK, August 07, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results and key operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. “Fiscal 2025 represented a year of disciplined execution and strategic…

READ MORE >
INBS strengthens FDA 510(k) package before planned U.S. entry

Intelligent Bio Solutions Strengthens FDA 510(k) Package with New Cybersecurity and Performance Data Ahead of Planned U.S. Market Launch

NEW YORK, August 06, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its Additional Information (“AI”) response to the United States Food and Drug Administration (“FDA”) as part of its ongoing 510(k) clearance process for planned entry to…

READ MORE >
Intelligent Bio Solutions Secures Major Drug Testing Tender with Leading London Transport Operator

Intelligent Bio Solutions Secures Major Drug Testing Tender with Leading London Transport Operator

NEW YORK, July 30, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major contract with one of London’s largest public transport operators, spanning 14 operational sites in greater London and employing over 4,400 staff. INBS’s…

READ MORE >
INBS to Strengthen FDA 510(k) Submission with New Data Demonstrating Ultra-Precise Fingerprint Sweat Detection.

Intelligent Bio Solutions to Strengthen FDA 510(k) Submission with New Positive Data Demonstrating Ultra-Precise Fingerprint Sweat Detection and Platform Resilience

NEW YORK, July 23, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful collection of new data that further reinforces the security and performance of its Intelligent Fingerprinting Drug Screening System, strengthening its FDA 510(k) submission. “Our ongoing dialogue with…

READ MORE >

Media

Media Contact

Sign Up

Subscribe to receive the latest news and updates from Intelligent Bio Solutions.